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Abstract
Molecular changes that affect mitochondrial glycolysis have been associated with the maintenance of tumor cells. Some
metabolic factors have already been described as predictors of disease severity and outcomes. This systematic review was
conducted to answer the question: Is the glycolytic pathway correlated with the prognosis of oral squamous cell carcinoma
(OSCC)? A search strategy was developed to retrieve studies in English from PubMed, Scopus, and ISI Web of Knowledge
using keywords related to squamous cell carcinoma, survival, and glycolytic pathway, with no restriction of publication date. The
search retrieved 1273 publications. After the titles and abstracts were analyzed, 27 studies met inclusion criteria. Studies were
divided into groups according to two subtopics, glycolytic pathways and diagnosis, which describe the glycolytic profile of OSCC
tumors. Several components of tumor energy metabolism found in this review are important predictors of survival of patients
with OSCC.
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Introduction
Two decades ago, cellular glucose metabolism and
cancer metabolism were not major branches of cancer
biology research. However, in the past 15 years, there has
been a growing interest in cancer metabolism, particularly
the energy metabolism of cancer cells. These topics have
now become an integral part of cancer biology, as are
signal transduction and transcription (1).
Cancer is characterized by a disorganized tissue
growth and the presence of tumor cells that are capable
of invading adjacent tissues and traveling through blood
and lymphatic vessels to form metastases (2). Oral squa-
mous cell carcinoma (OSCC) is the eighth most preva-
lent cancer worldwide, with more than 300,000 new cases
diagnosed every year. It is a public health problem because
of its poor prognosis, with a 5-year survival rate below
50% (3).
An OSCC prognosis is conventionally based on the
clinical Tumor, Nodes, Metastasis (TNM) classification.
However, this system does not predict patient survival
at the time of initial diagnosis. More sensitive prognostic
biomarkers may be useful to define patient follow-up and
treatment in the first stages of tumor development (4).
Because of that, the number of studies about metabolic
factors that promote tumor development and metastasis
has increased.
Molecular changes that affect glycolysis are asso-
ciated with the maintenance of the capacity of a tumor cell
to survive, proliferate, and invade tissues when exposed
to adverse conditions, such as hypoxia, lack of nutrients,
and immune responses (5,6).
Some metabolism factors, already described as pre-
dictors of disease severity and outcome, are metabolic
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biomarkers that may be useful in identifying OSCC
relapse in low- and high-risk patients (7–9). This systema-
tic review used a search strategy to retrieve studies to
answer the research question: Is the glycolytic pathway
correlated with the prognosis of OSCC?
Material and Methods
A search of the electronic databases PubMed, Scopus,
and ISI Web of Knowledge used keywords related to oral
squamous cell carcinoma, survival, and energy metabolism
to retrieve studies from the literature. The search strategy to
retrieve studies according to titles and abstracts was:
‘‘head and neck neoplasms’’ OR ‘‘mouth neoplasms’’ OR
‘‘oral squamous cell carcinoma’’ OR ‘‘head and neck squa-
mous cell carcinoma’’ OR ‘‘head and neck cancer’’ OR
‘‘oral cancer’’ AND ‘‘survival’’ OR ‘‘mortality’’ OR ‘‘prog-
nosis’’ OR ‘‘disease free survival’’ OR ‘‘survival analysis’’
AND ‘‘energetic metabolism’’ OR ‘‘energy metabolism’’
OR ‘‘glucose metabolism’’ OR ‘‘mitochondrial metabolism’’
OR ‘‘ATP production’’ OR ‘‘oxidative phosphorylation’’ OR
‘‘positron emission tomography’’ OR ‘‘glucose transpor-
ters’’. Only studies in English were included, with no date
restriction (last access May 2020), and duplicate studies
were discarded. After initial screening, studies were eva-
luated according to inclusion and exclusion criteria by two
reviewers (S.E.C.M. and F.A.G.). If the reviewers dis-
agreed, the study was evaluated again until a consensus
was reached. Study authors were not contacted to obtain
any additional information. This systematic review and
meta-analysis was registered with PROSPERO: CRD42018
106978.
Inclusion and exclusion criteria
Only studies about the effect of glycolytic metabolism
on the survival of human patients with OSCC were inclu-
ded. Studies using only animal models or cell cultures,
case reports, and literature reviews were excluded after
titles and abstracts were read. Studies were also excluded
if they did not include a survival analysis or follow-up time,
if they included patients that had not finished treatment, or
if their focus was on something other than glycolytic
variables. The following inclusion criteria were used in this
meta-analysis: 1) the publication explored the relationship
between GLUT1/TKTL1 expression and high SUVmax
and OSCC prognosis, such as overall survival (OS); 2) the
expression of GLUT1/TKTL1 and 2-deoxy-2-[fluorine-18]
fluoro-D-glucose (FDG) uptake was detected in tumor
tissue; 3) the expression of GLUT1/TKTL1 was measured
by the standard methods of immunohistochemistry and
RT-PCR with the corresponding cut-off value; 4) there
were sufficient, clear, and available data to extract or esti-
mate hazard ratios (HR) and 95% confidence interval (CI);
5) each study had a size greater than twenty individuals;
studies with small n could impair precision through
increasing heterogeneity; 6) studies were published in
English; and 7) the meta-analysis was restricted to original
articles (no expert opinions, editorials, or reviews).
Statistical analysis
The software Comprehensive Meta-Analysis version 3
(downloaded from http://www.meta-analysis.com) was
employed to integrate and analyze data.
The effect size is reported as HR and the correspond-
ing 95%CI. A pooled HR 41 suggested a poor prognosis
of patients with GLUT1/TKTL1 high-expression and high
SUVmax, whereas HR o1 entailed a better one. I2 and
Q-test indicated the degree of inconsistency across the
included trails, I2450% and Po0.05 indicated uncom-
promising heterogeneity (10,11). Fixed effects model or
random-effects model was chosen for the low or high hete-
rogeneity analysis, respectively. Sensitivity analysis was
conducted via excluding low-quality studies and inter-
changing random effect model and fixed effect model
among included trials to ensure the stability of pooled data.
Moreover, Egger’s weighted regression test and Begg’s
rank correlation test were applied to scrutinize publication
bias amongst included studies. A P-value o0.05 indicated
statistical significance. All analyses adopted in this article
were totally based on previously published studies; there-
fore, no ethical approval and consent from patients were
required.
Results
The initial search retrieved 1273 studies. After 221
duplicates were discarded, an evaluation of titles and
abstracts resulted in 72 studies for full-text reading, after
which 45 other studies were excluded (Figure 1). This
review, therefore, included 27 studies. The studies inclu-
ded were classified according to two subtopics: i) glycol-
ysis pathway and ii) diagnosis. These subtopics describe
the metabolic profile of OSCC tumors. Supplemen-
tary Tables S1 and S2 provide information about study
selection.
Glycolytic pathway
Eleven studies evaluated markers related to glycolysis
pathway: glucose transporter 1 (GLUT1), transketolase-
like 1 (TKTL1B), L-lactate dehydrogenase B chain (LDHB),
lactate dehydrogenase 5 (LDH5), pyruvate kinase (PKM2),
fructose-bisphosphate aldolase C expression (AldoC),
mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase
(HMGCS2), and binding protein Apo10 (Apo10) (12–20).
Four studies (14,18,21,22) used immunohistochemistry
(IHC) to examine the correlation of GLUT1 expression
levels with prognosis. GLUT1 was analyzed in 385 OSCC
biopsies with a mean/median follow-up interval of 17.6 to
72 months. Low and high GLUT1 expression levels were
analyzed using univariate and multivariate tests. In all
studies, GLUT-1 expression was significantly correlated
with disease-specific survival, and higher protein levels
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were associated with worse prognosis and shorter median
survivals.
Five studies (13,15,17,19,20) described the enzymes
AldoC, PKM2, LDHB, and LDH5. Low and high levels of
AldoC mRNA and protein expression, determined by
IHC, correlated with survival. High expression levels of
PKM2, LDHB, and LDH5 were significantly associated
with poorer survival, while patients with tumors expressing
low AldoC mRNA had longer survivals (P=0.001). Also,
OSCC patients with low HMGCS2 mRNA (12) and Apo10
and TKTL1B (23) protein expression survived significantly
longer than those with high expression levels. Results
suggested that these metabolic factors related to the
glycolysis pathway may play a key role in oral carcinoma
progression.
GLUT-1 expression and OSCC overall survival
The combined analysis of 5 studies (13,14,16,18,21)
showed that high GLUT-1 expression was related to
worse OS (pooled HR=2.927, 95%CI: 2.121–4.041,
z-value=6.530 P=0.000) (Figure 2A). Due to the non-
significant heterogeneity among included studies (I2=
0.000 P= 0.650), a fixed effect model was performed to
pool HRs. The results for Begg’s test and Egger’s test
revealed that there was no significant publication bias for
all analyses (Table 1; Figure 3).
Diagnosis
Positron emission tomography-computed tomography
(PET-CT) with FDG is a diagnostic tool that uses glucose
cell absorption to identify tumor volume and localization.
PET-CT uses parameters such as the standardized
uptake value (SUV), hypoxic volume (HV), metabolic
tumor volume (MTV), and total lesion glycolysis (TLG).
Fifteen of the studies in this review reported data about
FDG PET-CT findings and patient survival. One of these
studies has already been mentioned in the analysis of
studies about GLUT1. These studies used different values
of SUV to classify OSCC tumors according to low or high
SUVmax levels (16,22,24–35). Regardless of subgroup or
protocol, all these studies found that high levels of SUV
before surgery or follow-up predicted adverse outcomes
for patients with OSCC. Using the same tool, five studies
evaluated MTV and TLG alone or in combination with
SUVmax (24,25,30,34–36), and some found that both MTV
and TLG might be prognostic for the survival of patients with
oral cancer.
For meta-analysis we included the data of 8 combi-
ned studies (25,27,29,31,33,34,37,38). The high SUVmax
parameter was related to worse OS in OSCC (pooled
HR=4.042, 95%CI: 2.573–6.348, z-value=6.063, P=0.000)
(Figure 2B). Due to the low heterogeneity among included
studies (I2=0.000 P=0.706), a fixed effect model was
performed to pool HRs. The results for Begg’s test and
Egger’s test revealed that there was significant publication
bias (Table 1; Figure 4).
Discussion
Molecular oral cancer changes result in lesions that
develop in a series of histopathologic stages (39,40).
Some of these molecular mechanisms are involved in
tumor metabolism. Our review focused on the literature
about the impact of tumor glycolytic factors on the survival
of patients with OSCC.
Numerous studies have investigated metabolic changes
in cancer, but this review found only 27 studies that met
our inclusion criteria and discussed the role of metabolism
in the prognosis and survival of patients with oral cancer.
Ten studies evaluated specific markers of the glycolysis
pathway, and ten others used PET-CT as a diagnostic
method. One study used both the GLUT1 marker and PET-
CT. The glycolytic enzymes PKM2, PDK1, and HK2 are
greatly important in the functionality of glycolytic and
Figure 1. Study flow diagram for the literature search and selection of articles for this systematic review and meta-analysis.
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mitochondrial activity, and the studies included here
confirmed the positive regulation of oxygen-dependent
and oxygen-independent energy production.
All glycolytic pathway markers expressed in tumor cells
and included in this review were associated with poorer
patient prognosis (Figure 5). GLUT-1 high expression was
significantly correlated with shorter OS (Figure 2A) and
these results are similar to a meta-analysis of (41), which
specifically evaluated the GLUT-1 expression in OSCC and
its correlation with shorter OS. Cancer cells produce ATP
via glycolysis mainly, and not through the tricarboxylic
acid cycle or oxidative phosphorylation. Consequently,
Figure 2. A, Correlation between GLUT-1 and overall survival in oral squamous cell carcinoma (OSCC) (HR=2.553, 95%CI: 1.828–
3.564, P=0.000, fixed effect model). B, Correlation between positron emission tomography-computed tomography with 2-deoxy-2-
[fluorine-18]fluoro-D-glucose (FDG) standardized uptake value-max parameter and overall survival in OSCC (HR=4.042, 95%CI: 2.573–
6.348, P=0.000, fixed effect model). GLUT-1: glucose transporter-1; HR: hazard ratio. See Supplementary Table S1 for the reference
numbers of the studies.









GLUT-1 and OS 5 0.80650 0.48721
SUVMax and OS 8 0.00937 0.00085
OS: overall survival.
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large amounts of glucose are transported into the cyto-
plasm to maintain high levels of ATP production. Cancer
cells express high levels of glucose transporters in the
cytoplasmic membrane, particularly GLUT1 and GLUT3
(42,43). GLUT-1 possesses high affinity and provides
potential energy for cellular growth. Overexpression of
GLUT-1 could facilitate growth and proliferation of tumor
cells through supporting the high metabolic glucose con-
sumption in the hypoxic tumor microenvironment (TME),
which means that changes of GLUT-1 levels can be influ-
enced by growth rate, oxygen supply, and malignant trans-
formation in TME (41).
This increase in the expression of glucose transporters
is affected by HIF-1, which also increases the expression
of the genes involved in the enzymatic breakdown of
glucose into pyruvate and of the enzymes involved in
pyruvate metabolism. In hypoxic cells, pyruvate is con-
verted into lactate by lactate dehydrogenase (LDH). How-
ever, in cancer cells, the intense transformation of pyruvate
into lactate persists with or without subsequent exposure to
oxygen, a historical phenomenon known as the Warburg
effect (44). According to Sun et al. (19) and Grimm et al.
(23), a high level of LDH is a predictor of poor survival in
patients with OSCC (13,19). LDH may contribute to the
increase of the lactate released into the extracellular space
and decrease pH levels in the tumor environment, pro-
moting cancer migration, invasion, and metastasis (45).
Lactate production is directly affected by pyruvate
levels. Pyruvate is converted from phosphoenolpyruvate
by pyruvate kinase, mainly through its isoform, PKM2,
which is expressed in both cancer and normal tissues and
seems to promote anabolic metabolism and the Warburg
effect (46,47). Additionally, the nuclear translocation of
PKM2 acts as a transcriptional factor that mediates epi-
thelial-mesenchymal transition (EMT) in colon cancer cells
(48). PKM2 overexpression is correlated with a poor
overall survival in oral, gastric, and bladder cancer
(49,50). Inflammation is controlled by several extracellular
Figure 3. Publication bias assessment for glucose transporter-1 (GLUT-1) and overall survival. A, Begg’s test (funnel plot) and B,
Egger’s test (precision plot).
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mediators and regulators including cytokines, growth
factors, and eicosanoids. The study of the impact of these
molecules (mainly interleukins) on energy metabolism is
pivotal, insofar as metabolism drives the differentiation,
migration, invasion, and immune evasion in TME, thus
facilitating tumor growth and metastasis (51). In the TME,
immune cells, including macrophages and lymphocytes,
depend on glycolysis (52) and recently some metabolic
intermediates have been suggested to be able to regulate
IL-1b and IL-6, e.g., succinate, that stabilize hypoxia-
inducible factor-1a (HIF-1a) driving IL-1b and IL-6 produc-
tion. Another point is the glycolytic enzyme PKM2 that also
controls HIF-1a and thus IL-1b and IL-6 induction (53,54).
This scenario is mechanistically dependent on glycoly-
tic activity and glucose-induced reactive oxygen species
(ROS) production by the mitochondria, while molecular
analyses linked mitochondrial overload to excessive pro-
duction of ROS. ROS production within macrophages
promotes the dimerization of the glycolytic redox-sensing
enzyme PKM2. Dimeric PKM2 acts as a protein kinase and
phosphorylates the transcription factor STAT3. Phosphory-
lated STAT3 (PSTAT3) directly increases IL-1b and IL-6
transcription. Nuclear PKM2 specifically functions as a
regulator of cytokine production, as basic metabolic regul-
ators affect cellular behavior directly (55,56).
TKTL1 seems to be the key enzyme in a recently
described metabolic pathway that binds to the pentoses-
phosphate pathway and links the anaerobic degradation
of glucose to the production of fatty acids via production of
acetyl-CoA (57). In the glycolytic pathway, the activation of
the TKTL1 gene leads to oxygen-independent metabo-
lism, increasing glucose intake and lactic acid formation.
In addition, it contributes to proliferation, repression of the
immune system, angiogenesis, invasion, metastasis, and
resistance to treatment (58). The expression of the TKTL1
protein is significantly correlated with increased tumor
size, invasion, lymph node metastasis, and TNM stage in
gastric cancer (55).
Figure 4. Publication bias assessment for positron emission tomography-computed tomography standardized uptake value-max and
overall survival. A, Begg’s test (funnel plot) and B, Egger’s test (precision plot).
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This review revealed that high expressions of HMGCS2
and AldoC are associated with a poor prognosis in OSCC.
HMGCS2 is an enzyme involved in both the conversion of
fatty acids into carbon derivatives and ketogenesis (56).
Ketone bodies may be vital fuel in ketogenesis for tumor
initiation or metastasis. Therefore, ketone bodies are a
potential high energy resource that can enable a tumor to
grow even when cut off from a blood supply. Mitochondrial
HMGCS2, the rate-limiting enzyme, catalyzes the first
reaction in ketogenesis. Chen et al. (12) found that
HMGCS2 enhances invasion and metastasis via activa-
tion of the Src signaling pathway through interaction with
PPARa into OSCC cells. When Src is activated, it not only
induces cancer cell growth and survival, but also promo-
tes the reorganization of the actin cytoskeleton to invade
and reduce cell-cell and cell-matrix adhesion, which
ultimately further facilitates motility and invasion (12).
Patients with OSCC and low HMGCS2 expression seem
to survive significantly longer than those with a high
HMGCS2 expression level (12).
High expression of AldoC, an enzyme that participates
in the conversion of fructose-1,6-bisphosphate into gly-
ceraldehyde-3-phosphate and dihydroxyacetone phos-
phate, is associated with migration and invasion, and its
expression is associated with prognosis and cell migra-
tion (17).
Figure 5. Flow diagram showing the impact of each marker on the energy metabolism of tumor cells evaluated by meta-analysis. The+
and – symbols indicate increase and decrease of marker expression, respectively. GLUT-1: glucose transporter 1; TKTL-1:
transketolase like-1; SUVmax: standard uptake value maximum; AldoC: fructose-bisphosphate aldolase C; PKM2: pyruvate kinase
isoform M2; HMGCS2: mitochondrial hydroxymethylglutaryl-CoA synthase; LDHB: lactate dehydrogenase B; OSCC: oral squamous cell
carcinoma; TCA: tricarboxylic acid; OAA: oxalacetate acid; MCP: mitochondrial pyruvate carrier; MCT: monocarboxylate transporter.
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Different tumors and tumor cell populations use glu-
cose in different ways. The availability of nutrients deter-
mines that some cells in some tumors are predominantly
glycolytic, while others primarily have a metabolic pheno-
type for oxidative phosphorylation (1,6). In the studies
reviewed here, an increased glucose uptake, identified
using PET-CT, was correlated with a poor prognosis
(Figure 2B).
Data about age, tumor type, location, and TNM, as
well as the methods used to evaluate metabolic markers,
were different in the studies included in this review, which
precluded a definition of which marker might be the best
choice to establish a prognosis, an interesting question
that should be investigated in future studies. However, in
general, metabolic changes were associated with a poor
survival prognosis (Figure 5).
The data selected to compose the meta-analysis may
be influenced by the publication bias. Publication bias
means the tendency for published results to be system-
atically different from the reality. Analysis of clinical trials
with a protocol registered in the ClinicalTrial.gov registry
base revealed that less than 70% of studies are published
(57). Failure to publish results may be due to the author’s
decision or study sponsor, who do not submit unfavorable
findings for publication, or scientific journals, which may
not be interested in disclosing negative results (without
statistical significance).
In systematic reviews, the presence of this bias can be
identified by means of a funnel and statistical tests (Table
1; Figure 4). The use of these techniques is based on
questions of estimation and precision. Inaccurate studies,
generally carried out with small sample sizes, may find
positive or negative results (statistically significant or not)
due to random chances. To acquire the data of more
precise studies, we tried contacting the authors without
success and this situation obligated us to include small
studies (small N) in the meta-analysis (Figures 3 and 4;
Table 1).
Moreover, several primary studies that investigated
prognosis and overall survival lacked important data, such
as odds ratio, hazard ratio, relative risks, and respective
confidence intervals. We must take into account that in
systematic reviews with meta-analysis, those data are
pivotal for a precise conclusion. To solve this problem
there are two options: sending e-mails to the authors
asking for the raw data or calculate the hazard ratios and
the 95%CI from Kaplan-Meier curves. Regarding e-mails,
several times the authors did not respond, which makes it
very difficult to perform precise analyses. Our suggestion,
therefore, is that studies about prognosis and survival
should all show descriptive statistics as discussed before.
Conclusions
Most elements of tumor energy metabolism included in
this review were important survival predictors for patients
with OSCC. In the past, research used several character-
istics of cancer models, such as sustained proliferative
signs, evasion of growth suppressors, resistance to cell
death, replicative immortality, induction of angiogenesis,
and activation of invasion and metastasis. With the
development of cancer research, an important feature
has emerged: the deregulation of cell energy metabolism,
which may bring significant advances to treatments. This
systematic review evaluated whether some markers
associated with changes in glycolysis, pentose phosphate
pathway, and lipid metabolism may be useful when using
IHC or RT-PCR findings. We found that high expression
levels of GLUT1, pyruvate kinase isoform M2, lactate
dehydrogenase isoform 5, TKTL1, and HMGCS2 are
associated with poor outcome in OSCC. Further studies
should focus on the role of metabolic factors in cell
behavior as differentiation, migration, and metastasis with
the findings being important to improve new adjuvant
treatments and develop prognostic biomarkers.
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